Pharmaceutical governance system for costly drugs through human rights due diligence.
Where this comes from
- Record sourced from PubMed, PMID 41218971.
- Also identified by DOI 10.1136/bmj-2023-074982 and PMC identifier 12599527.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The obligations and responsibilities of governments and drug companies to increase access to costly new drugs should be grounded in international human rights, write <b>Trudo Lemmens and colleagues</b>